France· FR:65014745
DORZOLAMIDE/TIMOLOL CRISTERS 20 mg/mL + 5 mg/mL, collyre en solution
A medicinal product containing maléate de timolol + chlorhydrate de dorzolamide, registered in France by CRISTERS, on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- MALÉATE DE TIMOLOL + CHLORHYDRATE DE DORZOLAMIDE
- Manufacturer
- CRISTERS
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009300262501 flacon(s) polyéthylène moyenne densité (PEMD) compte-gouttes (incorporé) polyéthylène basse densité (PEBD) de 5 mlEUR 5.53
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Maléate de timolol + chlorhydrate de dorzolamide in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomCodimaz 20mg/ml / 5mg/ml eye dropsScope Ophthalmics Ltd
- CzechiaAMIPTICZaklady Farmaceutyczne Polpharma SA, Starogard Gdański
- GermanyCosduoSanten Oy
- SwedenCosopt 20 mg/ml + 5 mg/ml Ögondroppar, lösningSanten Oy
- United StatesCOSOPTThea Pharma Inc.
- SpainARZOTIM 20 MG/ML + 5 MG/ML COLIRIO EN SOLUCIONTiedra Farmaceutica S.L.
- FinlandCosoptSanten Oy
- PolandCosoptSanten Oy
Authorised across Europe · EMA
The same active substance is authorised in 29 EEA countries. Names it is sold under:
- Austria · Cosopt, Cosopt Sine
- Belgium · Cosopt, Cosopt Sine Conservans
- Bulgaria · Амиптифри, Дорзасопт
- Cyprus · Cosopt, Cosopt Imulti
- Czechia · Amiptic, Cosopt
- Germany · Cosduo, Cosopt
- Denmark · Cosopt, Cosopt Imulti Ukonserveret
- Estonia · Cosopt, Dorzolamide/Timolol Elvim
- Spain · Arzotim, Cosduo
- Finland · Cosopt, Cosopt Sine
- United Kingdom (Northern Ireland) · Codimaz, Cosopt
- Greece · Apleona, Cosopt
- Croatia · Apleona, Cosopt
- Hungary · Cosopt, Cosopt Multi
- Ireland · Cosopt, Cosopt Preservative-Free
- Iceland · Arzotilol, Cosopt Sine
- Italy · Betaclar, Cosopt
- Lithuania · Cosopt, Cosopt Sine
- Luxembourg · Cosopt, Cosopt Sine Conservans
- Latvia · Amiptic, Amiptinon
- Malta · Cosopt Preservative-Free
- Netherlands · Cosopt, Cosopt Conserveermiddelvrij, Oogdruppels, Oplossing, Flacon Voor Eenmalig Gebruik
- Norway · Apleona, Cosopt
- Poland · Cosopt, Cosopt Pf
- Portugal · Cosopt, Cosopt Multi
- Romania · Cosopt, Cosopt Fără Conservant
- Sweden · Cosopt, Cosopt Sine
- Slovenia · Cosopt, Cosopt Brez Konzervansa
- Slovakia · Cosopt, Cosopt Free
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b8263fc0-6389-4e43-986d-e6580cc1fa83 GET /v1/drugs/b8263fc0-6389-4e43-986d-e6580cc1fa83?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "65014745",
"date_amm": "2015-08-05",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "MALÉATE DE TIMOLOL + CHLORHYDRATE DE DORZOLAMIDE",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "collyre en solution",
"voies_administration": "ophtalmique",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about maléate de timolol + chlorhydrate de dorzolamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.